Advanced search
Publication Cover
Journal of Medical Economics Volume 20, 2017 - Issue 8
Submit an article Journal homepage
1,582
Views
14
CrossRef citations to date
0
Altmetric
Cardiovascular

Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands

Marieke HeisenPharmerit International, Rotterdam, The Netherlands; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-5339-6606
ORCID Icon,
Maarten J. TreurPharmerit International, Rotterdam, The Netherlands;
,
Harald E. HeemstraBayer B.V., Mijdrecht, The Netherlands;
,
Eric B. W. GiesenBayer Pharma AG, Berlin, Germany;
&
Maarten J. PostmaUnit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands; ;Department of Epidemiology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands; ;Institute of Science in Healthy Aging & healthcaRE (SHARE), UMCG, University of Groningen, Groningen, The Netherlands
Pages 813-824 | Received 29 Mar 2017, Accepted 01 May 2017, Published online: 25 Jun 2017

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Kerstin Folkerts, Julie Broughton, Usman Sheikh & Sasha Mckaig. (2019) Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK. Journal of Medical Economics 22:11, pages 1179-1191.
Read now
Philip S. Wells, Anthonie W. A. Lensing, Lloyd Haskell, Bennett Levitan, François Laliberté, Michael Durkin, Veronica Ashton, Yongling Xiao, Concetta Crivera, Dominique Lejeune, Jeff Schein & Patrick Lefebvre. (2018) Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results. Journal of Medical Economics 21:6, pages 587-594.
Read now

Articles from other publishers (12)

Marianne Luyendijk, Agnes Jager, Sanne M. Buijs, Sabine Siesling, Carin A. Uyl-de Groot & Hedwig M. Blommestein. (2023) Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer. PharmacoEconomics 41:8, pages 981-997.
Crossref
Siwaporn Niyomsri, Mantiwee Nimworapan, Wanwarang Wongcharoen & Piyameth Dilokthornsakul. (2023) Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis. International Journal of Environmental Research and Public Health 20:4, pages 3176.
Crossref
Ioannis T. Farmakis, Stefano Barco, Anna C. Mavromanoli, Giancarlo Agnelli, Alexander T. Cohen, George Giannakoulas, Charles E. Mahan, Stavros V. Konstantinides & Luca Valerio. (2022) Cost‐of‐Illness Analysis of Long‐Term Health Care Resource Use and Disease Burden in Patients With Pulmonary Embolism: Insights From the PREFER in VTE Registry. Journal of the American Heart Association 11:20.
Crossref
Ira L. Leeds, Bradford Sklow, Emre Gorgun, David Liska, Amy L. Lightner, Tracy L. Hull, Scott R. Steele & Stefan D. Holubar. (2022) Cost-Effectiveness of Aspirin for Extended Venous Thromboembolism Prophylaxis After Major Surgery for Inflammatory Bowel Disease. Journal of Gastrointestinal Surgery 26:6, pages 1275-1285.
Crossref
Ira L. Leeds, Joseph K. Canner, Sandra R. DiBrito & Bashar Safar. (2022) Do Cost Limitations of Extended Prophylaxis After Surgery Apply to Ulcerative Colitis Patients?. Diseases of the Colon & Rectum 65:5, pages 702-712.
Crossref
Muhammad Ajmal, Jacob Friedman, Qurat Ul Ain Riaz Sipra & Tom Lassar. (2021) Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review. Cardiovascular Therapeutics 2021, pages 1-9.
Crossref
Lisa A de Jong, Annette W G van der Velden, Marinus van Hulst & Maarten J Postma. (2020) Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism. BMJ Open 10:11, pages e039057.
Crossref
Asma Rashki Kemmak, Ali Abutorabi & Vahid Alipour. (2020) Economic Evaluation of Rivaroxaban Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Knee Replacement and Total Hip Replacement: A Systematic Review. Clinical Drug Investigation 40:8, pages 715-725.
Crossref
Gülsüm Şeyma KOCA & Yusuf ÇELİK. (2020) VENÖZ TROMBOEMBOLİZMİN MALİYETLERİ VE EKONOMİK YÜKÜNÜN BELİRLENMESİNE İLİŞKİN SİSTEMATİK BİR DERLEME: FARMAEKONOMİK ÖNLEYİCİ BİR TEDAVİ OLARAK DMAHA SYSTEMATIC REVIEW OF THE DETERMINATION OF COSTS AND ECONOMIC BURDEN OF VENOUS THROMBOEMBOLISM: LMWH AS A PHARMAECONOMIC PREVENTIVE THERAPY. İşletme Bilimi Dergisi 8:1, pages 67-95.
Crossref
Ira L. Leeds, Joseph K. Canner, Sandra R. DiBrito & Bashar Safar. (2019) Justifying Total Costs of Extended Venothromboembolism Prophylaxis After Colorectal Cancer Surgery. Journal of Gastrointestinal Surgery 24:3, pages 677-687.
Crossref
Ira L. Leeds, Sandra R. DiBrito, Joseph K. Canner, Elliott R. Haut & Bashar Safar. (2019) Cost-Benefit Limitations of Extended, Outpatient Venous Thromboembolism Prophylaxis Following Surgery for Crohn’s Disease. Diseases of the Colon & Rectum 62:11, pages 1371-1380.
Crossref
Zanfina Ademi, Ella Zomer, Andrew Tonkin & Danny Liew. (2018) Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective. International Journal of Cardiology 270, pages 54-59.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.